These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 8299398)

  • 41. [Paclitaxel (Taxol)--drug of choice in ovarian cancer].
    Fishman A
    Harefuah; 1996 Apr; 130(8):557-60. PubMed ID: 8765885
    [No Abstract]   [Full Text] [Related]  

  • 42. [Effect of 2 different forms of chemotherapy on remission in patients with advanced ovarian cancer].
    Krommer K; Keller G; Csaba I; Garadnay B; Göcze P
    Zentralbl Gynakol; 1990; 112(17):1105-10. PubMed ID: 2264421
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Therapeutic effectiveness of various combination chemotherapy protocols in advanced epithelial ovarian cancer].
    Petru E; Schmähl D
    Geburtshilfe Frauenheilkd; 1986 Nov; 46(11):783-9. PubMed ID: 3803871
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chemotherapy for advanced epithelial ovarian cancer.
    Ozols RF
    Hematol Oncol Clin North Am; 1992 Aug; 6(4):879-94. PubMed ID: 1500391
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The value of platinum dose intensity in first-line therapy on subsequent disease follow-up of epithelial ovarian carcinoma].
    Gruböck K
    Wien Klin Wochenschr; 1994; 106(11):362-6. PubMed ID: 8053205
    [No Abstract]   [Full Text] [Related]  

  • 46. p53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen.
    Gadducci A; Cianci C; Cosio S; Carnino F; Fanucchi A; Buttitta F; Conte PF; Genazzani AR
    Anticancer Res; 2000; 20(6C):4793-9. PubMed ID: 11205220
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Treatment of patients with ovarian carcinoma: experimental and clinical studies].
    Kikuchi Y; Kita T; Iwano I; Miyauchi M; Oomori K; Kizawa I; Kato K
    Nihon Sanka Fujinka Gakkai Zasshi; 1988 Jul; 40(7):933-5. PubMed ID: 3418201
    [No Abstract]   [Full Text] [Related]  

  • 49. The results of a quantitative overview of chemotherapy in advanced ovarian cancer: what can we learn?
    Stewart LA; Parmar MK
    Bull Cancer; 1993 Feb; 80(2):146-51. PubMed ID: 8173166
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chemotherapy in ovarian carcinoma.
    Lund B; Hansen HH
    Cancer Surv; 1989; 8(3):681-91. PubMed ID: 2701088
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Platinum-based adjuvant chemotherapy for early-stage epithelial ovarian cancer: single or combination chemotherapy?
    Adams G; Zekri J; Wong H; Walking J; Green JA
    BJOG; 2010 Nov; 117(12):1459-67. PubMed ID: 20560942
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic factors for outcome of and survival after second-look laparotomy in patients with advanced ovarian carcinoma.
    Lund B; Williamson P
    Obstet Gynecol; 1990 Oct; 76(4):617-22. PubMed ID: 2216190
    [TBL] [Abstract][Full Text] [Related]  

  • 53. NICE guidance on bevacizumab in combination with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer.
    Dyer M; Richardson J; Robertson J; Adam J
    Lancet Oncol; 2013 Jul; 14(8):689-90. PubMed ID: 23706983
    [No Abstract]   [Full Text] [Related]  

  • 54. [Metastatic brain tumor after chemotherapy of ovarian cancer].
    Fukuda K; Chen JT; Fujimoto I; Yamauchi K; Hasumi K; Masubuchi K; Sakamoto A
    Gan No Rinsho; 1987 Jan; 33(1):115-8. PubMed ID: 3102810
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer.
    Huober J; Meyer A; Wagner U; Wallwiener D
    J Cancer Res Clin Oncol; 2002 Mar; 128(3):153-60. PubMed ID: 11935302
    [TBL] [Abstract][Full Text] [Related]  

  • 56. "Cisplatin plus etoposide as second-line treatment in advanced ovarian carcinoma".
    De Lena M; Lorusso V; Romito S
    Cancer Treat Rep; 1987; 71(7-8):790. PubMed ID: 3607793
    [No Abstract]   [Full Text] [Related]  

  • 57. Ovarian cancer.
    CA Cancer J Clin; 1987; 37(4):252-5. PubMed ID: 3111654
    [No Abstract]   [Full Text] [Related]  

  • 58. Ultrasounds examination during polychemotherapy for ovarian cancer.
    Montoneri C; Bellia V; Currao G; Giudice I; Panella M; Garozzo G
    Eur J Gynaecol Oncol; 1985; 6(2):114-5. PubMed ID: 3896812
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Process and outcome of care for patients with ovarian cancer.
    Lawton F; Blackledge G
    Br Med J (Clin Res Ed); 1985 Nov; 291(6506):1421-2. PubMed ID: 3933692
    [No Abstract]   [Full Text] [Related]  

  • 60. Postneoadjuvant Chemotherapy Response in Advanced Ovarian Cancer: Radiological and Clinical Implications.
    Shampain KL; Wasnik AP
    Acad Radiol; 2020 Jul; 27(7):958-959. PubMed ID: 32204988
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.